Gracell Biotechnologies Inc. (GRCL) Tops Q4 EPS by 2c

Gracell Biotechnologies Inc. (NASDAQ: GRCL) reported Q4 EPS of ($0.06), $0.02 better than the analyst estimate of ($0.08).

For earnings history and earnings-related data on Gracell Biotechnologies Inc. (GRCL) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c
• L3Harris CEO steps down amid conduct review, shares drop